“Meeting to Seek Support for Early Breast Cancer Recurrence Patients Held by Rep. Lee Jong-seong and Health Experts”

This paper-Rep. Lee Jong-seong held a ‘meeting to seek support for patients with high risk of early breast cancer recurrence’

As cancer survival rates increase, quality of life after treatment is emphasized, preventing cancer recurrence has become more important. especially Early breast cancer has a high recurrence rate and occurs frequently in the 40s and 50s, a pivotal generation in our society.crazy This is why voices that raise awareness of the risk of recurrence of early breast cancer and consider support policies for them continue to be raised.

Accordingly, this paper held a ‘meeting to seek support for patients at high risk of early breast cancer recurrence’ with Rep. Lee Jong-seong of the People’s Power of the National Assembly Health and Welfare Committee today (9th).

Today’s meeting was an extension of the ‘Discussion on National Support for Managing the Risk of Recurrence of Breast Cancer Patients’ held on the 7th of last month, and a more in-depth discussion was held on the necessary national support policies for early breast cancer patients.

Today’s meeting was attended by Congressman Lee Jong-seong, Health Kyunghyang CEO Cho Chang-yeon, Director Han Jeong-sun, Seoul National University Bundang Hospital Hemato-Oncology Professor Kim Ji-hyun, Gangnam Severance Hospital Oncology Professor Kim Ji-hyung.

In particular, the meeting Exchange opinions more freely with a focus on improving the treatment environment for early breast cancer patientsIt was done in a way that

Professors Kim Ji-hyeon and Kim Ji-hyeong, who feel the difficulties of early breast cancer patients most closely, said, “Breast cancer patients study very hard on their own, so unlike other countries, many patients in Korea ask why the treatment is so expensive.” There is no such thing,” he said.

Professor Jihyung Kim said, “Unlike in the past, now Several new drugs have been developed that can lower the risk of recurrence, and treatment options have become very numerous.“But Even drugs whose clinical effects have been confirmed are not covered by insurance, so only patients who can afford them are choosing new drugs.” he said.

actually The newest treatments for breast cancer have confirmed that they can increase the treatment effect compared to the existing standard treatment through clinical studies targeting patients with a high risk of early breast cancer recurrence. many there is.

photo-layout image photo_70641 max-width-600 float-center" data-idxno="70641" data-type="photo" style="display:inline-block">

Professor Kim Ji-hyung said, “There are so many subtypes of breast cancer, and the treatments are all different for each subtype.”If all of the treatments that have clinically proven efficacy are covered, the recurrence of more early breast cancer patients will be prevented and the quality of life will be improved.”he expressed.

Professor Jihyun Kim In order for effective new drugs not to become a pie in the sky, the Korean system itself must be changed.pointed out.

Professor Kim Ji-hyun said, “Compared to the advanced level of medical care in Korea, the policy is going backwards.” “As countless new drugs are being developed, Now, breaking the existing frame of applying 5% for severe diseases to all drugs, we are thinking about a new frame for the application of insurance coverage for new drugs.I have to do it,” he said forcefully.

photo-layout image photo_70640 max-width-600 float-center" data-idxno="70640" data-type="photo" style="display:inline-block">

Rep. Lee Jong-seong expressed deep sympathy for these opinions and expressed his will to make efforts.

Rep. Lee Jong-seong said, “Usually, patients with rare diseases express great frustration at the situation where they freely use drugs in foreign countries and cannot use them in Korea.” I will feel very frustrated with the reality that I can not write in .

“We will carefully review the data on the 4 to 5 drugs that have not crossed the threshold of reimbursement, present them to the Health Insurance Policy Deliberation Committee, and actively recommend them to the Ministry of Health and Welfare and HIRA so that the application of reimbursement can be reviewed.”We will continue to pay attention to the improvement of the treatment environment for early breast cancer patients and do our best in our current position.”he said.

Professor Kim Ji-hyung said, “As early breast cancer is a very emotionally difficult disease due to fear of recurrence, it is a great hope in itself that drugs for them have been developed and can be used.” If there are more early breast cancer new drugs covered by insurance, more patients will be able to actively seek treatment with hope.”he reiterated.

Professor Kim Ji-hyun said, “Breast cancer patients As someone’s mother and wife, the future of the family depends on one of them.“as “I hope that our society will pay more attention and seriously consider policies for them.” he asked again.

Meanwhile, at the meeting, it was also mentioned that there is a need to improve public awareness of breast cancer and the efforts of the academic community.

Han Jeong-sun, director, said, “Breast cancer Improving public awareness of cancer that can be cured unconditionally“In addition, as sufficient supporting data is required to apply insurance coverage for new drugs, Academia should also continue to voice its voice to the government by accumulating early breast cancer research data such as cost-effectiveness studies.”he said. He added, “The media Through the delivery of correct information, we will continue to raise awareness about early breast cancer so that better support policies can be established.I will pay,” he added.

Copyright © Health Trend Unauthorized reproduction and redistribution prohibited